Browsing Tag
Firebrick Pharma
2 posts
Firebrick Pharma (ASX:FRE) surges as Nasodine Phase 3 trial confirms 40% cold relief
Firebrick Pharma’s Phase 3 Nasodine trial confirms 40% symptom relief in cold patients. Discover how this could accelerate global sales and investor interest.
Nasodine Nasal Spray phase 3 clinical trial : Firebrick Pharma completes 82% patient recruitment
Firebrick Pharma, an ASX-listed pharmaceutical company, announced that it has successfully enrolled 160 subjects in the confirmatory phase…